Novavax, Inc (NASDAQ:NVAX) Stock Decline


Boston, MA – (Financialstrend) – 03/24/2014 – Novavax, Inc (NASDAQ:NVAX) announced the execution of a certain contract modification for extension of the base-period of performance of the company’s current contract with the United States Department of Health & Human Services & Biomedical Advanced Research & Development Authority for advanced development of Novavax, Inc (NASDAQ:NVAX)’s recombinant seasonal & pandemic influenza vaccines. This contract had been originally awarded in 2011 February, with funding of upto $97M over the initial base-period that ended in February 2014. The company & the BARDA have now agreed to amend this agreement to allow Novavax, Inc (NASDAQ:NVAX) to continue with accessing the remaining $97M in the base- period funding right through to Sep 2014.

These funds will now support the upcoming Phase-II trial for the company’s H7N9 vaccine- candidate with Matrix-M, and the activities related to the company’s quadrivalent seasonal- influenza vaccine. BARDA will be able to dedicate up to $79M in additional funds for supporting Novavax, Inc (NASDAQ:NVAX)’s later-stage development of the vaccines, during the option period that is currently anticipated to add 2 years to the overall-performance period. Development of the seasonal & pandemic influenza products over the last 3 years under this contract with the BARDA has allowed Novavax, Inc (NASDAQ:NVAX) to refine & develop influenza vaccine-products even as they deliver important clinical-trial results from their seasonal quadrivalent, the avian H5N1, and more recently, the avian H7N9 studies.

While the original development plans of the company had anticipated using the full-amount of the contracted base-period funding within the three-year period, some scope changes & development efforts resulted in the delayed development timelines. Extending this base period allows Novavax, Inc (NASDAQ:NVAX) to continue to access the remainder base-period budget as they initiate a pandemic H7N9 Phase II study early in 2014 and also for additional Phase II & Phase III influenza clinical-trials, which they expect will take place during the option period of the contract said the company’s president and Chief Executive Officer, said Stanley C. Erck.

Subscribe to get your free report!

* indicates required
*Past performance is not a predictor of future results. All investing involves risk of loss and individual investments may vary. The examples provided may not be representative of typical results. Your capital is at risk when you invest – you can lose some or all of your money. Never risk more than you can afford to lose.By submitting your information you agree to the terms of our Privacy Policy • Cancel Newsletter Any Time.This is a FREE service from Finacials Trend. Signing up for our FREE daily e-letter also entitles you to receive this report. We will NOT share your email address with anyone.